[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352740-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352740-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","emerging-crispr-approaches-for-countering-immune-evasion-insight-from-recent-studies","Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies","","Cancer immunotherapy has become a key option for treating cancer, offering meaningful potential beyond surgery, radiation, and conventional chemotherapy. The approach strengthens the host’s immune defense using immune checkpoint blockades, especially PD-1 and CTLA-4, and adoptive cellular therapies such as CAR, TCR, and TIL. Tumors often resist immunotherapy through immune evasion mechanisms, reducing effectiveness. This review summarizes these evasion pathways and explains how CRISPR/Cas9 gene editing can enhance immunotherapy by modifying immune checkpoints, TILs, and CAR-T cells. It also discusses emerging base editors to engineer NK cells and improve outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/emerging-crispr-approaches-for-countering-immune-evasion-insight-from-recent-studies/352740/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/emerging-crispr-approaches-for-countering-immune-evasion-insight-from-recent-studies/352740.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main strategies of cancer immunotherapy discussed in the document?","Question",{"text":63,"@type":64},"The document highlights immune checkpoint blockade (ICB) and adoptive cellular therapies (ACTs). ICB targets regulators such as CTLA-4 and PD-1/PD-L1, while ACTs include CAR, TCR, and TIL therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do tumors reduce the effectiveness of cancer immunotherapy?",{"text":68,"@type":64},"Tumors employ immune evasion mechanisms, including lowering antigen expression and increasing immune checkpoint proteins like PD-L1 in the tumor microenvironment (TME). These actions hinder immune targeting and destruction even after immunotherapy reactivates immune responses.",{"name":70,"@type":61,"acceptedAnswer":71},"How does CRISPR/Cas9 support improved cancer immunotherapy outcomes?",{"text":72,"@type":64},"CRISPR/Cas9 is presented as a gene-editing tool to explore and positively alter immune system genes. The review emphasizes editing immune checkpoints, modifying TILs and CAR-T cells, and disrupting genes that facilitate immune evasion, thereby improving effectiveness.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352740,1790433969,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Review  \nEmerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies  \nSadam Abubakar 1, Latifat Abdulsalam 1, Lamin Fatty 2, Rimsha Kanwal 3, Muhammad Naeem 4 and Irshad Ahmad 1,5, *  \nAcademic Editor: Mariana Malvicini  \nReceived: 23 January 2026  \nRevised: 15 March 2026  \nAccepted: 17 March 2026  \nPublished: 24 March 2026  \nCorrection Statement: This article has been republished with a minor change. The change does not affect the scientific content of the article and further details are available within the backmatter of the website version of this article.  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Bioengineering, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran 31261, Saudi Arabia; [g202315670@kfupm.edu.sa](g202315670@kfupm.edu.sa) (S.A.); [g202210360@kfupm.edu.sa](g202210360@kfupm.edu.sa) (L.A.)  \n2 Department of Chemical Sciences, University of Padua, Via Marzolo 1, 35131 Padua, Italy; [lamin.fatty@studenti.unipd.it](lamin.fatty@studenti.unipd.it)  \n3 Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore 54000, Pakistan; [rimshakanwal391@gmail.com](rimshakanwal391@gmail.com)  \n4 Department of Cell and Developmental Biology, Weill Cornell Medicine, Cornell University, 1300 York Avenue, New York, NY 10065, USA; [naeempunia@gmail.com](naeempunia@gmail.com)  \n5 Interdisciplinary Research Center for Membranes and Water Security, King Fahd University of Petroleum and Minerals (KFUPM), Dhahran 31261, Saudi Arabia  \n* Correspondence: [irshad@kfupm.edu.sa](irshad@kfupm.edu.sa); Tel.: +966-13-8608393  \nAbstract  \nCancer immunotherapy has recently become an essential approach for treating cancer, showing considerable promise as a substitute for surgery, radiation therapy, and conventional chemotherapy. It primarily aims to boost the host’s natural defense system to combat cancer malignancies by utilizing components of immune checkpoint blockades (ICBs), mainly programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), along with elements of adoptive cellular therapies (ACTs) like Chimeric Antigen Receptor (CAR) therapy, T Cell Receptor (TCR) therapy and Tumor-Infiltrating Lymphocyte (TIL) therapy. However, cancer cells tend to undermine the effectiveness of cancer immunotherapeutic strategies by employing one or more immune evasion mechanisms. This review briefly highlights how key mechanisms of cancer immune evasion confer resistance to immunotherapy and how the Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 (CRISPR)/Cas9 systems, as gene-editing tools, are poised to enhance cancer immunotherapy for treating challenging cancers. We emphasize that (CRISPR/Cas9) systems can be used to explore and positively alter the genes of the immune system, boosting the effectiveness of cancer immunotherapy by editing immune checkpoints, TILs, and CAR-T cells, and disrupting genes, facilitating tumors’ evasion of the immune system. Furthermore, we highlight the growing interest in emerging base editor technology to engineer natural killer (NK) cells to overcome NK-cell-based immunotherapy challenges, particularly human leukocyte antigens (HLA)-mediated limitations, and to engineer CAR-T cells for improved immunotherapy outcomes.  \nKeywords: cancer immunotherapy; immune evasion; gene editing; tumor infiltration; tumor microenvironment (TME)  \n1. Introduction  \n1.1. Background on Cancer Immunotherapy  \nCancer immunotherapy has gained significant attention as a safer and more effective alternative to conventional cancer treatment methods like surgery, radiation, and  \nchemotherapy [1] . Traditional cancer therapies often fail to eliminate metastatic tumors, increasing the risks of recurrence. Additionally, they usually cause damage to surrou","cbCaikQEf382IPbR","https://ap.wps.com/l/cbCaikQEf382IPbR","pdf",2661388,31,"English","# Abstract\n# Keywords\n# 1. Introduction\n## 1.1. Background on Cancer Immunotherapy","[{\"question\":\"What are the main strategies of cancer immunotherapy discussed in the document?\",\"answer\":\"The document highlights immune checkpoint blockade (ICB) and adoptive cellular therapies (ACTs). ICB targets regulators such as CTLA-4 and PD-1/PD-L1, while ACTs include CAR, TCR, and TIL therapies.\"},{\"question\":\"How do tumors reduce the effectiveness of cancer immunotherapy?\",\"answer\":\"Tumors employ immune evasion mechanisms, including lowering antigen expression and increasing immune checkpoint proteins like PD-L1 in the tumor microenvironment (TME). These actions hinder immune targeting and destruction even after immunotherapy reactivates immune responses.\"},{\"question\":\"How does CRISPR/Cas9 support improved cancer immunotherapy outcomes?\",\"answer\":\"CRISPR/Cas9 is presented as a gene-editing tool to explore and positively alter immune system genes. The review emphasizes editing immune checkpoints, modifying TILs and CAR-T cells, and disrupting genes that facilitate immune evasion, thereby improving effectiveness.\"}]","Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies | PDF",1790101168,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1db5f1041598be84d246c7db68b67d9.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8029248b6cc007c788a540c54536d344.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa88d048ba0a9f1abf140d08c5807b16.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95fc2fa56caa0862dd2bf834c1f4022c.webp",980,1385]